Iris Roth
Net worth: 576 713 $ as of 2024-04-29
Profile
Iris Roth worked as Vice President-Global Medicine at AstraZeneca PLC.
She then worked as Vice President-Medicine Development Leader at GlaxoSmithKline LLC from 2019 to 2023.
After that, she worked as Chief Operating Officer at Kartos Therapeutics, Inc. In 2023, she worked as Chief Operating Officer at Zentalis Pharmaceuticals, Inc. Dr. Roth completed her undergraduate degree from the University of California, Berkeley, and her doctorate from The University of California, San Francisco.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-02-28 | 52,500 ( 0.07% ) | 576 713 $ | 2024-04-29 |
Former positions of Iris Roth
| Companies | Position | End |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Chief Operating Officer | 2023-10-09 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Chief Tech/Sci/R&D Officer | 2023-01-31 |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Chief Operating Officer | - |
Training of Iris Roth
| University of California, Berkeley | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| ASTRAZENECA PLC | Health Technology |
| Private companies | 2 |
|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Health Technology |
- Stock Market
- Insiders
- Iris Roth